Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sigrun Hallmeyer

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Oncoimmunology|October 15, 2021
An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic MelanomaMerve Hasanov, Denái R Milton, William H Sharfman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2021
Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable MelanomaRobert H I Andtbacka, Brendan Curti, Gregory A Daniels, et al.
Immunotherapy|November 8, 2023
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry studyJohn M Kirkwood, Lisa A Kottschade, Robert R McWilliams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2017
Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario GuidelineJeanne Carter, Christina Lacchetti, Barbara L Andersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2024
Cannabis and Cannabinoids in Adults With Cancer: ASCO GuidelineIlana M Braun, Kari Bohlke, Donald I Abrams, et al.
Melanoma Research|October 28, 2017
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600ESigrun Hallmeyer, Rene Gonzalez, David H Lawson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2022
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline UpdateAndrea Eisen, Mark R Somerfield, Melissa K Accordino, et al.
Cancer Journal (Sudbury, Mass.)|January 22, 2014
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United StatesLawrence Flaherty, Omid Hamid, Gerald Linette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in MelanomaDaniel J Olson, Zeynep Eroglu, Bruce Brockstein, et al.
Journal for Immunotherapy of Cancer|September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanomaElizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Oncoimmunology|October 15, 2021
An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic MelanomaMerve Hasanov, Denái R Milton, William H Sharfman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2021
Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable MelanomaRobert H I Andtbacka, Brendan Curti, Gregory A Daniels, et al.
Immunotherapy|November 8, 2023
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry studyJohn M Kirkwood, Lisa A Kottschade, Robert R McWilliams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2017
Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario GuidelineJeanne Carter, Christina Lacchetti, Barbara L Andersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2024
Cannabis and Cannabinoids in Adults With Cancer: ASCO GuidelineIlana M Braun, Kari Bohlke, Donald I Abrams, et al.
Melanoma Research|October 28, 2017
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600ESigrun Hallmeyer, Rene Gonzalez, David H Lawson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2022
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline UpdateAndrea Eisen, Mark R Somerfield, Melissa K Accordino, et al.
Cancer Journal (Sudbury, Mass.)|January 22, 2014
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United StatesLawrence Flaherty, Omid Hamid, Gerald Linette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in MelanomaDaniel J Olson, Zeynep Eroglu, Bruce Brockstein, et al.
Journal for Immunotherapy of Cancer|September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanomaElizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.
Pageof 3